Orexigen Therapeutics, Inc. (OREX) Reaches $0.85 Yearly Low; Molina Healthcare (MOH) Sellers Decreased By 6.18% Their Shorts

February 14, 2018 - By Elijah Rosenthal

Molina Healthcare Incorporated (NYSE:MOH) had a decrease of 6.18% in short interest. MOH’s SI was 9.02 million shares in February as released by FINRA. Its down 6.18% from 9.61M shares previously. With 1.07M avg volume, 9 days are for Molina Healthcare Incorporated (NYSE:MOH)’s short sellers to cover MOH’s short positions. The SI to Molina Healthcare Incorporated’s float is 20.79%. The stock decreased 1.21% or $0.91 during the last trading session, reaching $74.55. About 78,956 shares traded. Molina Healthcare, Inc. (NYSE:MOH) has risen 48.61% since February 14, 2017 and is uptrending. It has outperformed by 31.91% the S&P500.

The stock of Orexigen Therapeutics, Inc. (NASDAQ:OREX) hit a new 52-week low and has $0.79 target or 7.00% below today’s $0.85 share price. The 8 months bearish chart indicates high risk for the $16.09 million company. The 1-year low was reported on Feb, 14 by Barchart.com. If the $0.79 price target is reached, the company will be worth $1.13 million less. The stock decreased 7.39% or $0.068 during the last trading session, reaching $0.852. About 229,236 shares traded. Orexigen Therapeutics, Inc. (NASDAQ:OREX) has declined 15.00% since February 14, 2017 and is downtrending. It has underperformed by 31.70% the S&P500.

Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products primarily in the United States, Europe, and South Korea. The company has market cap of $16.09 million. It offers Contrave for the treatment of obesity. It currently has negative earnings. The firm also offers Contrave under the Mysimba brand name.

Analysts await Orexigen Therapeutics, Inc. (NASDAQ:OREX) to report earnings on March, 27. They expect $-2.06 earnings per share, up 22.85% or $0.61 from last year’s $-2.67 per share. After $-1.35 actual earnings per share reported by Orexigen Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 52.59% negative EPS growth.

Among 5 analysts covering Orexigen Therapeutics (NASDAQ:OREX), 2 have Buy rating, 1 Sell and 2 Hold. Therefore 40% are positive. Orexigen Therapeutics had 12 analyst reports since August 5, 2015 according to SRatingsIntel. The company was upgraded on Tuesday, September 15 by RBC Capital Markets. The firm has “Market Perform” rating given on Friday, December 4 by Wells Fargo. The company was maintained on Saturday, August 8 by Piper Jaffray. The rating was upgraded by Zacks on Wednesday, August 5 to “Sell”. The firm earned “Underperform” rating on Friday, December 11 by Bank of America. The company was downgraded on Wednesday, March 16 by JMP Securities. The rating was maintained by RBC Capital Markets with “Outperform” on Friday, November 6. The rating was maintained by Piper Jaffray with “Overweight” on Tuesday, October 6. The firm has “Buy” rating by JP Morgan given on Monday, August 10.

Molina Healthcare, Inc. provides Medicaid-related solutions to meet the health care needs of low-income families and individuals; and to assist state agencies in their administration of the Medicaid program in the United States. The company has market cap of $4.45 billion. It operates through three divisions: Health Plans, Molina Medicaid Solutions, and Other. It currently has negative earnings. The Health Plans segment operates health plans in 12 states.

Investors sentiment increased to 1.08 in 2017 Q3. Its up 0.04, from 1.04 in 2017Q2. It increased, as 43 investors sold Molina Healthcare, Inc. shares while 61 reduced holdings. 23 funds opened positions while 89 raised stakes. 58.60 million shares or 8.44% more from 54.04 million shares in 2017Q2 were reported. Weaver C Barksdale And Assocs holds 0.11% of its portfolio in Molina Healthcare, Inc. (NYSE:MOH) for 1,484 shares. Ubs Asset Mgmt Americas has invested 0% of its portfolio in Molina Healthcare, Inc. (NYSE:MOH). Alpha Windward Limited Liability Company reported 8,520 shares. Riverhead Mngmt Limited Com holds 0.01% of its portfolio in Molina Healthcare, Inc. (NYSE:MOH) for 2,887 shares. 32,108 are owned by Texas Permanent School Fund. 717,124 were accumulated by Bancshares Of Ny Mellon Corp. Menta Cap Ltd Company has invested 0.07% of its portfolio in Molina Healthcare, Inc. (NYSE:MOH). Rhumbline Advisers invested in 88,529 shares or 0.01% of the stock. Thompson Davis Inc invested in 355 shares. Principal Fincl Grp Inc owns 192,315 shares. Assetmark has invested 0% in Molina Healthcare, Inc. (NYSE:MOH). Jpmorgan Chase And Communications invested in 0.02% or 1.04 million shares. Palisade Capital Mngmt Ltd Liability Corporation Nj reported 109,998 shares. Eagle Asset Mgmt owns 0.06% invested in Molina Healthcare, Inc. (NYSE:MOH) for 165,529 shares. Massachusetts-based Numeric Investors Lc has invested 0.02% in Molina Healthcare, Inc. (NYSE:MOH).

Since August 17, 2017, it had 0 buys, and 26 sales for $47.75 million activity. DENTINO WILLIAM sold $5.85M worth of stock or 67,500 shares. MOLINA JOHN C sold $1.50M worth of Molina Healthcare, Inc. (NYSE:MOH) on Wednesday, October 18. 250 Molina Healthcare, Inc. (NYSE:MOH) shares with value of $15,958 were sold by ROMNEY RONNA. MOLINA J MARIO MD also sold $1.02 million worth of Molina Healthcare, Inc. (NYSE:MOH) on Tuesday, October 3. On Monday, August 21 the insider Rubino Lisa A sold $324,293. The insider BAYER TERRY sold $256,931. 1,000 Molina Healthcare, Inc. (NYSE:MOH) shares with value of $60,000 were sold by ORLANDO STEVEN J.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts